PMID- 9552062
OWN - NLM
STAT- MEDLINE
DCOM- 19980512
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 16
IP  - 4
DP  - 1998 Apr
TI  - Conversion of interferon-induced, long-term cytogenetic remissions in chronic 
      myelogenous leukemia to polymerase chain reaction negativity.
PG  - 1526-31
AB  - PURPOSE: Interferon alfa (IFN-alpha) induces complete cytogenetic remission in a 
      significant minority of patients with chronic myelogenous leukemia (CML). To 
      date, use of the polymerase chain reaction (PCR) has suggested that residual 
      disease is present in virtually all these individuals at median follow-up 
      intervals of approximately 1 year after initial achievement of cytogenetic 
      remission. We sought to determine the PCR status of CML patients with very long 
      continuous complete cytogenetic remissions on IFN-alpha. PATIENTS AND METHODS: 
      Blood and/or bone marrow samples from 18 CML patients maintained in continuous 
      cytogenetic remission by IFN-alpha for at least 1 year were studied for residual 
      BCR-ABL mRNA by single-step reverse-transcriptase (RT)-PCR methodology, followed 
      by detection of the amplification product by the hybridization protection assay 
      (HPA). RESULTS: Ten of 18 patients showed RT-PCR negativity for BCR-ABL. The 
      median duration of continuous complete cytogenetic remission at the time of 
      sample collection for the negative patients was 42 months versus 21 months for 
      the patients whose tests remained positive (P = .05). CONCLUSION: Very long-term 
      follow-up of IFN-alpha-treated CML patients in continuous complete cytogenetic 
      remission is associated with a decrease in the number of BCR-ABL transcripts to a 
      level below that detectable by the RT-PCR assay used in this study.
FAU - Kurzrock, R
AU  - Kurzrock R
AD  - Department of Bioimmunotherapy, University of Texas, M.D. Anderson Cancer Center, 
      Houston 77030, USA.
FAU - Estrov, Z
AU  - Estrov Z
FAU - Kantarjian, H
AU  - Kantarjian H
FAU - Talpaz, M
AU  - Talpaz M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Interferon-alpha)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bone Marrow/*drug effects
MH  - Female
MH  - Fusion Proteins, bcr-abl/*drug effects/genetics
MH  - Humans
MH  - Interferon-alpha/*therapeutic use
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics/*therapy
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction/*methods
MH  - Remission Induction
MH  - Time Factors
MH  - Translocation, Genetic
EDAT- 1998/04/29 00:00
MHDA- 1998/04/29 00:01
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 1998/04/29 00:01 [medline]
PHST- 1998/04/29 00:00 [entrez]
AID - 10.1200/JCO.1998.16.4.1526 [doi]
PST - ppublish
SO  - J Clin Oncol. 1998 Apr;16(4):1526-31. doi: 10.1200/JCO.1998.16.4.1526.